SLC6A19 and phenylketonuria: These data provide the first clinical proof-of-mechanism that pharmacological inhibition of SLC6A19 mimics the Hartnup phenotype, observed with genetic loss of SLC6A19 function in humans, confirming the potential for this mechanism to combat the buildup of pathogenic amino acid levels in the context of PKU.